TAO Synergies Inc. (TAOX) is a Financials stock trading at $3.80 (as of 2026-08-21), with a market capitalization of $28.39M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Clinical-stage biopharmaceutical company developing a bryostatin‑1 platform for Alzheimer’s and other neurodegenerative/cognitive diseases. Also pivoting to a digital-asset treasury strategy focused on acquiring and staking TAO cryptocurrency.
TAO Synergies Inc. is a clinical-stage biopharmaceutical company developing a bryostatin-1 platform for Alzheimer’s and other neurodegenerative or cognitive diseases, and it is also pursuing a digital-asset treasury strategy by acquiring and staking TAO cryptocurrency.
Its economics are shaped less by recurring, reportable business-line revenue and more by two uncertain paths, clinical-stage biopharma progress and the performance of its TAO crypto treasury activity (acquiring and staking TAO).
Business quality (Weak): Limited visibility from the provided data, no official segment breakdown is available, the latest quarter reports 0.0B revenue with a deeply negative operating margin, and only one operating KPI is provided.
| Price | $3.80 |
| Market Cap | $28.39M |
| Price / Book | 2.23 |
| Price / Sales | 320.37 |
| Revenue (TTM) | $299061.00 |
| Net Margin | -9609.2% |
| Revenue Growth (YoY) | 2136.9% |
| EPS Growth (YoY) | -83.7% |
| Altman Z-Score | -0.62 (distress) |
| Sector P/E (Financials) | 15.1 |
| Industry P/E (Banking) | 13.0 |
| Top Institutional Holder | RENAISSANCE TECHNOLOGIES LLC ($579242.00) |
| Institutional Holders Tracked | 10 |
| Sector | Financials |
| Industry | Banking |
| CEO | Joshua N. Silverman |
| Employees | 4 |
| Country | US |
| IPO Date | 2025-07-02 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.